NZ737666A - Antibody binding to fcrn for treating autoimmune diseases - Google Patents

Antibody binding to fcrn for treating autoimmune diseases

Info

Publication number
NZ737666A
NZ737666A NZ737666A NZ73766615A NZ737666A NZ 737666 A NZ737666 A NZ 737666A NZ 737666 A NZ737666 A NZ 737666A NZ 73766615 A NZ73766615 A NZ 73766615A NZ 737666 A NZ737666 A NZ 737666A
Authority
NZ
New Zealand
Prior art keywords
fcrn
antibody
autoimmune diseases
receptor
antibody binding
Prior art date
Application number
NZ737666A
Other languages
English (en)
Inventor
Sung Wuk Kim
Seung Kook Park
Jae Kap Jeong
Hyea Kyung Ahn
Min Sun Kim
Eun Sun Kim
Hae-Young Yong
Dongok Shin
Yeon Jung Song
Tae Hyoung Yoo
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Publication of NZ737666A publication Critical patent/NZ737666A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rehabilitation Therapy (AREA)
NZ737666A 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases NZ737666A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
NZ726089A NZ726089A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
NZ737666A true NZ737666A (en) 2018-10-26

Family

ID=54358928

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ737666A NZ737666A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases
NZ726089A NZ726089A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ726089A NZ726089A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Country Status (21)

Country Link
US (6) US10544226B2 (enExample)
EP (2) EP4241852A3 (enExample)
JP (1) JP6449441B2 (enExample)
KR (2) KR101889466B1 (enExample)
CN (2) CN106459215B (enExample)
AU (2) AU2015253915B2 (enExample)
CA (2) CA3095295C (enExample)
DK (1) DK3137504T5 (enExample)
EA (1) EA038470B1 (enExample)
ES (1) ES2952583T3 (enExample)
FI (1) FI3137504T3 (enExample)
HU (1) HUE062403T2 (enExample)
IL (2) IL248159B (enExample)
MX (2) MX382284B (enExample)
NZ (2) NZ737666A (enExample)
PL (1) PL3137504T3 (enExample)
PT (1) PT3137504T (enExample)
RS (1) RS64542B1 (enExample)
SA (1) SA516380194B1 (enExample)
SG (1) SG11201608208VA (enExample)
WO (1) WO2015167293A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
KR20190015704A (ko) * 2016-04-25 2019-02-14 신티뮨, 인크. 인간화된 친화성 성숙 항-fcrn 항체
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
MX2019015065A (es) * 2017-06-15 2020-08-03 UCB Biopharma SRL Metodo para tratamiento de trombocitopenia inmunitaria.
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
JP7518821B2 (ja) 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
CN113423426B (zh) * 2018-11-06 2025-02-18 依牧诺万科学有限公司 使用抗FcRn抗体治疗格雷夫斯眼病的方法
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
EP4061486A1 (en) * 2019-11-19 2022-09-28 Immunovant Sciences GmbH Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
WO2021160116A1 (zh) * 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR20220001482A (ko) * 2020-06-29 2022-01-05 한올바이오파마주식회사 항-FcRn 항체에 대한 제형
JP7765457B2 (ja) * 2020-08-06 2025-11-06 ステレクシス セラピューティクス，エルエルシー Ｉｌ－８抗体及びその使用方法
WO2022098084A1 (ko) * 2020-11-06 2022-05-12 고려대학교 산학협력단 Fc 알파 수용체 결합 항체
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神（北京）生物制药股份有限公司 特异性识别fcrn的抗体及其用途
US20250026814A1 (en) * 2021-11-16 2025-01-23 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
AU2023281650A1 (en) * 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
AU2023313033A1 (en) * 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
JP2025528527A (ja) 2022-09-06 2025-08-28 イミュノバント・サイエンシズ・ゲーエムベーハー 抗ＦｃＲＮ抗体を用いたグレーブス病の治療方法
KR20250084991A (ko) 2022-09-06 2025-06-11 이뮤노반트 사이언시스 게엠베하 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법
JP2026508415A (ja) 2023-03-08 2026-03-10 イムノバント サイエンシズ ゲーエムベーハー ポリソルベート賦形剤を含む高濃度タンパク質製剤およびその製造方法
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
IL325970A (en) 2023-07-16 2026-03-01 argenx BV Methods for treating chronic inflammatory demyelinating polyneuropathy
AU2024370990A1 (en) 2023-10-31 2026-05-21 IMVT Corporation Methods of improving anti-fcrn therapies
IL328082A (en) 2023-11-06 2026-06-01 Momenta Pharmaceuticals Inc Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588B (zh) * 2024-10-17 2026-03-06 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用
WO2026136830A1 (en) * 2024-12-20 2026-06-25 Paragon Therapeutics, Inc. Anti-fcrn antibodies and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2008538919A (ja) 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー ＦｃＲｎ抗体およびその使用
CA2637929A1 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US8273351B2 (en) * 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
KR20130071961A (ko) 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Also Published As

Publication number Publication date
CN111138540A (zh) 2020-05-12
EP3137504A4 (en) 2018-02-28
DK3137504T3 (da) 2023-08-14
EP4241852A3 (en) 2023-11-15
AU2015253915B2 (en) 2018-05-10
IL280613B (en) 2021-12-01
KR101954906B1 (ko) 2019-03-08
KR20160145779A (ko) 2016-12-20
EP4241852A2 (en) 2023-09-13
AU2018203582A1 (en) 2018-06-14
CN106459215A (zh) 2017-02-22
SG11201608208VA (en) 2016-11-29
BR112016025319A2 (pt) 2017-12-12
CA2945086A1 (en) 2015-11-05
US10544226B2 (en) 2020-01-28
CN111138540B (zh) 2023-07-25
EP3137504A1 (en) 2017-03-08
DK3137504T5 (en) 2024-10-14
EP3137504B1 (en) 2023-05-10
ES2952583T3 (es) 2023-11-02
US20190135917A1 (en) 2019-05-09
PL3137504T3 (pl) 2023-10-16
RS64542B1 (sr) 2023-09-29
MX2016014210A (es) 2017-05-01
HUE062403T2 (hu) 2023-10-28
CA3095295C (en) 2023-01-10
SA516380194B1 (ar) 2020-10-14
IL280613A (en) 2021-03-25
FI3137504T3 (fi) 2023-08-07
US20170210801A1 (en) 2017-07-27
EA038470B1 (ru) 2021-09-01
KR101889466B1 (ko) 2018-08-21
PT3137504T (pt) 2023-08-18
AU2018203582B2 (en) 2019-05-02
US11613578B2 (en) 2023-03-28
AU2015253915A1 (en) 2016-12-01
US20230235063A1 (en) 2023-07-27
IL248159B (en) 2021-02-28
IL248159A0 (en) 2016-11-30
MX382284B (es) 2025-03-13
US20250026835A1 (en) 2025-01-23
EA201692192A1 (ru) 2017-04-28
JP6449441B2 (ja) 2019-01-09
CA2945086C (en) 2020-12-29
NZ726089A (en) 2017-12-22
CA3095295A1 (en) 2015-11-05
MX2021005193A (es) 2021-09-08
KR20180093128A (ko) 2018-08-20
CN106459215B (zh) 2019-12-24
US20200109201A1 (en) 2020-04-09
JP2017522043A (ja) 2017-08-10
WO2015167293A1 (en) 2015-11-05
US20240092913A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
MX2021005193A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
PH12020552178A1 (en) Anti-il36r antibodies
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
JOP20200161B1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
TW201613970A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JO3568B1 (ar) عوامل ربط cd123 واستخداماتها
PH12016501366A1 (en) Novel anti-baff antibodies
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
PE20180499A1 (es) Anticuerpos de union a tau
TN2018000419A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof.
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
WO2016205551A3 (en) Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2020 BY CPA GLOBAL

Effective date: 20190314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2021 BY FB RICE PTY LTD

Effective date: 20200205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2022 BY FB RICE PTY LTD

Effective date: 20210203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2023 BY FB RICE PTY LTD

Effective date: 20220208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2024 BY FB RICE PTY LTD

Effective date: 20230203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2025 BY FB RICE PTY LTD

Effective date: 20240216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2026 BY FB RICE PTY LTD

Effective date: 20250225